1stOncology™: Cancer Intelligence Service – Page 13119 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Xenetic Biosciences, Inc. to Present at BIO Investor Forum

On October 16, 2019 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, reported that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at BIO Investor Forum on Wednesday, October 23, 2019 at 2:45 PM PT in San Francisco, CA (Press release, Xenetic Biosciences, OCT 16, 2019, View Source [SID1234542307]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

As part of his presentation, Mr. Eisenberg will provide a Company overview and discuss the Company’s novel CAR T platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas. Xenetic is currently advancing the development program for XCART to confirm the positive preclinical results shown to date and to demonstrate a more attractive safety profile than existing therapies.

In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live audio webcast of the presentation will be available on the IR Calendar in the Investors section of Xenetic’s website (www.xeneticbio.com) or by accessing the conference website here. Within three days of the event, a webcast replay will be made available on the Company’s website.

About BIO Investor Forum

Now in its 17th year, the BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables, therapeutic workshops, company presentations, and BIO One-on-One Partnering meetings. For more information, please visit the conference website here.

4SC and Netherlands Cancer Institute Collaborate on Clinical Evaluation of Domatinostat in the Neoadjuvant Setting in Melanoma

On October 16, 2019 4SC AG (4SC, FSE Prime Standard: VSC) reported a collaboration with the Netherlands Cancer Institute (Stichting Het Nederlands Kanker Instituut (NKI) – Antoni van Leeuwenhoek Ziekenhuis) in Amsterdam to evaluate domatinostat in combination with checkpoint blockade in a "Multicenter Phase 1b Study testing the Neoadjuvant Combination of Domatinostat, Nivolumab, and Ipilimumab, in RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma – DONIMI" (Press release, 4SC, OCT 16, 2019, View Source [SID1234542306]).

Immunotherapy, and particularly checkpoint inhibitors like anti-PD-1 (e.g. Nivolumab) and anti-CTLA4 (Ipilimumab), are increasingly investigated not only in the advanced unresectable or metastatic setting but also in earlier stages of disease. The rationale for such treatment is to activate the immune system before resection of the tumor to generate an immune memory and prevent recurrence of the disease. On the basis of some encouraging data published by the International Neoadjuvant Melanoma Consortium (INMC; View Source), innovative combination approaches will now be tested to optimize the treatment in a more personalized manner where domatinostat is a promising combination partner.

Jason Loveridge, Ph.D., CEO of 4SC: "It is getting clearer and clearer that immunotherapy for cancer is most effective when used early in disease progression and we believe the neoadjuvant setting offers a great potential for protecting patients from recurrence of their malignancy after resection, potentially leading to a much higher number of cured patients with resectable, high-risk melanoma. Prof. Blank and his collaborators within the INMC have already made remarkable progress in this highly innovative field in melanoma and the NKI is a worldwide leading cancer center in the treatment of melanoma and other indications in the neoadjuvant setting. We are grateful entering such collaboration with the NKI and looking forward to the initiation of the DONIMI study in the near future."

Prof. Dr. Christian Blank, NKI: "It is exciting to see what we have achieved with neoadjuvant immunotherapy in melanoma within the INMC during the last few years. However there´s still a way to go to implement a standard neoadjuvant treatment in melanoma. Additional combination approaches to modulate the tumor microenvironment and the patients´ immune system remains a priority so as to optimize and personalize treatment for patients with melanoma, and potentially impact the treatment of patients with other cancers. For example, we do not know yet which patients require double neoadjuvant checkpoint inhibition and who can be treated with neoadjuvant PD-1 blockade alone. Based on preclinical and early clinical data, epigenetic modulation with domatinostat in combination with checkpoint blockade might be a promising approach in the neoadjuvant setting. In the DONIMI study, Domatinostat will be one of the first compounds tested in a personalized neoadjuvant combination trial implemented by INMC researchers from Sydney and Amsterdam. We are much looking forward to enroll the first patients later this year."

Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

On Octobber 16, 2019 Sutro Biopharma, Inc. (NASDAQ: STRO) reported that the company will present at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held Oct. 26-30, 2019, in Boston (Press release, Sutro Biopharma, OCT 16, 2019, View Source [SID1234542305]). The presentation will include both new preclinical efficacy data and initial dose escalation safety data from the company’s ongoing Phase I study of STRO-002 in patients with ovarian cancer. STRO-002 is a novel antibody-drug conjugate (ADC) targeting the clinically validated folate receptor-α (FRα), an antigen known to be overexpressed in ovarian cancer. Sutro discovered and manufactures STRO-002 using its proprietary XpressCF+ cell-free protein synthesis technology.

Poster Presentation Details:

Antitumor activity of STRO-002, a novel folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)

Date: Tuesday, Oct. 29, 2019

Time: 12:30 p.m. – 4:00 p.m. EDT

Location: Hall D, Hynes Convention Center, Boston, MA, United States

Poster Session: Tubulin-interacting Agents

Abstract Number: C095

The abstract was published today on the AACR (Free AACR Whitepaper) website. The poster will be accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company’s website at www.sutrobio.com on the day of the poster presentation.

Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

On October 16, 2019 Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, reported that data from four of the Company’s pipeline programs will be presented in poster sessions at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held October 26-30, 2019 in Boston, MA (Press release, Deciphera Pharmaceuticals, OCT 16, 2019, View Source [SID1234542304]).

A copy of each abstract will be available via the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) website.

Details of the four poster sessions are as follows.

Poster Title: Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors
Session Title: Immune Modulators
Author: Filip Janku, MD, University of Texas MD Anderson Cancer Center
Session Date and Time: Monday, October 28, 12:30-4:00 PM ET
Location: Hall D, Hynes Convention Center
Abstract Number: B055

Poster Title: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers
Session Title: New Molecular Targets
Author: Bryan D. Smith, PhD, Deciphera Pharmaceuticals
Session Date and Time: Monday, October 28, 12:30-4:00 PM ET
Location: Hall D, Hynes Convention Center
Abstract Number: B129

Poster Title: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Author: Ping Chi, MD, PhD, Memorial Sloan Kettering Cancer Center
Session Date and Time: Tuesday, October 29, 12:30-4:00 PM ET
Location: Hall D, Hynes Convention Center
Abstract Number: C077

Poster Title: Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Author: Matthew H. Taylor, MD, Oregon Health & Science University
Session Date and Time: Tuesday, October 29, 12:30-4:00 PM ET
Location: Hall D, Hynes Convention Center
Abstract Number: C087

About Ripretinib

Ripretinib is an investigational tyrosine kinase switch control inhibitor that was engineered to broadly inhibit KIT and PDGFRα mutated kinases by using a unique dual mechanism of action that regulates the kinase switch pocket and activation loop. Ripretinib is currently in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors, or GIST, systemic mastocytosis, or SM, and other cancers. Ripretinib inhibits initiating and secondary KIT mutations in exons 9, 11, 13, 14, 17, and 18, involved in GIST, as well as the primary D816V exon 17 mutation involved in SM. Ripretinib also inhibits primary PDGFRα mutations in exons 12, 14 and 18, including the exon 18 D842V mutation, involved in a subset of GIST. In June 2019, the U.S. FDA granted Fast Track Designation to ripretinib for the treatment of patients with advanced GIST who have received prior treatment with imatinib, sunitinib and regorafenib.

Deciphera Pharmaceuticals has an exclusive license agreement with Zai Lab (Shanghai) Co., Ltd. for the development and commercialization of ripretinib in Greater China (MainlandChina, Hong Kong, Macau and Taiwan). Deciphera Pharmaceuticals retains development and commercial rights for ripretinib in the rest of the world.

About Rebastinib

Rebastinib is an investigational, orally administered, potent and selective inhibitor of the TIE2 kinase, the receptor for angiopoietins, an important family of vascular growth factors in the tumor microenvironment that also activate pro-tumoral TIE2 expressing macrophages. In a Phase 1 clinical study, biomarker data have demonstrated rebastinib-induced increases in the TIE2 ligand angiopoietin 2, secondary to TIE2 inhibition. Rebastinib is currently being evaluated in a Phase 1b/2 clinical study in combination with paclitaxel (NCT03601897), in a Phase 1b/2 clinical study in combination with carboplatin (NCT03717415), and in an investigator sponsored Phase 1b trial in patients with metastatic breast cancer in combination with paclitaxel or eribulin (NCT02824575).

About DCC-3014

DCC-3014 is an investigational, orally administered, potent and highly selective inhibitor of CSF1R. DCC-3014 was designed using the Company’s proprietary switch control kinase inhibitor platform to selectively bind to the CSF1R switch pocket. DCC-3014 has greater than 100-fold selectivity for CSF1R over other closely related kinases and has an even greater selectivity for CSF1R over approximately 300 other human kinases. CSF1R controls the differentiation and function of macrophages including Tumor Associated Macrophages (TAMs) whose density within certain tumors including cancers of the breast, cervix, pancreas, bladder and brain correlates with poor prognosis. Tumors induce TAMs to suppress a natural immune response mediated by cytotoxic T-cells, a type of lymphocyte that would otherwise eradicate the tumor; a process known as macrophage checkpoints. Through inhibition of CSF1R, DCC-3014 has in preclinical studies demonstrated potent macrophage checkpoint inhibition as both a single agent and in combination with PD1 inhibitors and other T-cell checkpoint inhibitors. DCC-3014 is currently being evaluated in a Phase 1 clinical study. For more information about the clinical trial design please visit www.clinicaltrials.gov (NCT03069469).

About DCC-3116

DCC-3116 is a potential first-in-class small molecule designed to inhibit cancer autophagy, a key tumor survival mechanism, by inhibiting the ULK kinase. Subject to favorable investigational new drug (IND)-enabling studies and filing and activation of an IND, expected in mid-2020, Deciphera intends to develop DCC-3116 for the potential treatment of mutant RAS cancers in combination with inhibitors of downstream RAS effector targets including RAF, MEK, or ERK inhibitors as well as with direct inhibitors of mutant RAS.

Navire Pharma, a BridgeBio subsidiary, to Present Data Showing Potential of SHP2 Inhibitor IACS-13909 in Treatment-Resistant Lung Cancer

On October 16, 2019 Navire Pharma, Inc., a BridgeBio Pharma, Inc. subsidiary developing small molecule inhibitors of the protein tyrosine phosphatase SHP2 (Src homology 2 domain-containing phosphatase), reported preclinical data demonstrating the potential for the Company’s SHP2 inhibitor to lung cancer tumor cells that have acquired resistance to EGFR inhibitors, which are common targeted cancer medicines (Press release, Navire Pharma, OCT 16, 2019, View Source [SID1234542303]). The data will be presented at AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) on October 29, 2019.

"Our work with MD Anderson’s Institute for Applied Cancer Science (IACS) adds to the growing body of evidence that SHP2 is an important node in MAPK signaling and supports combining a SHP2 inhibitor with an RTK inhibitor in RTK-driven cancers," said Shafique Virani, CEO of Navire Pharma. "The aim of BridgeBio’s BBP-398 program is to rapidly translate this exciting science into the clinic to evaluate the program’s potential to manage treatment-resistant cancers. We are preparing the program to be ready for clinical testing in 2020."

In a poster entitled "Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance," Yuting Sun, Ph.D., a member of the Institute for Applied Cancer Science at MD Anderson Cancer Center, from which Navire licensed its SHP2 inhibitors, will present preclinical data demonstrating that the allosteric SHP2 inhibitors were able to reduce growth of EGFR-driven non-small cell lung cancer (NSCLC) in vitro and in vivo. Importantly, IACS-13909 enhanced the anti-tumor activity of osimertinib, a front-line therapy for EGFR mutated NSCLC, when used in combination with osimertinib in preclinical models.

SHP2, a conserved protein tyrosine phosphatase, is a critical node in growth factor, cytokine and integrin signaling, all of which are important in the progression of cancer. SHP2 regulates multiple downstream signaling pathways including RTK/MAPK and the adaptive immune response through checkpoint inhibition. Alterations in RTK/MAPK and checkpoint inhibition pathways are common in cancer. Thus, targeting SHP2 may offer a potential new approach to treat this disease.